Nothing Special   »   [go: up one dir, main page]

BR112019022307A2 - Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza. - Google Patents

Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza. Download PDF

Info

Publication number
BR112019022307A2
BR112019022307A2 BR112019022307-0A BR112019022307A BR112019022307A2 BR 112019022307 A2 BR112019022307 A2 BR 112019022307A2 BR 112019022307 A BR112019022307 A BR 112019022307A BR 112019022307 A2 BR112019022307 A2 BR 112019022307A2
Authority
BR
Brazil
Prior art keywords
patient
pirrolopyrimidine
virus replication
derivatives useful
replication inhibitors
Prior art date
Application number
BR112019022307-0A
Other languages
English (en)
Inventor
C. Jacobson Irina
David Feese Michael
Sk Lee Sam
Original Assignee
Cocrystal Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma, Inc. filed Critical Cocrystal Pharma, Inc.
Publication of BR112019022307A2 publication Critical patent/BR112019022307A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

métodos para inibir a replicação de vírus da influenza em uma amostra biológica ou um paciente, para reduzir a quantidade de vírus da influenza em uma amostra biológica ou um paciente e para tratar influenza em um paciente compreendem administrar à referida amostra biológica ou ao paciente uma quantidade segura e eficaz de um composto representado por qualquer das fórmulas i-iii, ou um sal farmaceuticamente aceitável do mesmo. uma composição farmacêutica compreende uma quantidade segura e eficaz de tal composto ou sal farmaceuticamente aceitável do mesmo e um transportador, adjuvante ou veículo farmaceuticamente aceitável.
BR112019022307-0A 2017-04-24 2018-04-24 Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza. BR112019022307A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762489167P 2017-04-24 2017-04-24
US62/489,167 2017-04-24
PCT/US2018/028986 WO2018200425A1 (en) 2017-04-24 2018-04-24 Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

Publications (1)

Publication Number Publication Date
BR112019022307A2 true BR112019022307A2 (pt) 2020-05-26

Family

ID=62117141

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019022307-0A BR112019022307A2 (pt) 2017-04-24 2018-04-24 Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza.

Country Status (19)

Country Link
US (1) US11014941B2 (pt)
EP (1) EP3615545B1 (pt)
JP (1) JP7165721B2 (pt)
KR (1) KR102598466B1 (pt)
CN (1) CN110637022B (pt)
AU (1) AU2018257778B2 (pt)
BR (1) BR112019022307A2 (pt)
CA (1) CA3059449A1 (pt)
DK (1) DK3615545T3 (pt)
EA (1) EA039181B1 (pt)
ES (1) ES2901875T3 (pt)
IL (1) IL269900B (pt)
MX (1) MX2019012759A (pt)
NZ (1) NZ757442A (pt)
PH (1) PH12019502376A1 (pt)
PL (1) PL3615545T3 (pt)
SG (1) SG11201909478UA (pt)
TW (1) TWI778052B (pt)
WO (1) WO2018200425A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081751A1 (en) * 2018-10-17 2020-04-23 Cocrystal Pharma, Inc. Combinations of inhibitors of influenza virus replication
MX2021005582A (es) * 2018-11-13 2021-06-30 Cocrystal Pharma Inc Formulaciones de terapias contra la gripe.
WO2020218316A1 (ja) * 2019-04-26 2020-10-29 日産化学株式会社 アリールスルホン酸エステル化合物の製造方法
US20230265107A1 (en) * 2020-07-10 2023-08-24 Sichuan Haisco Pharmaceutical Co., Ltd. Pb2 inhibitor, and preparation method therefor and use thereof
US20240254477A1 (en) * 2020-11-23 2024-08-01 The Regents Of The University Of California Methods and compositions for linking rna stem loops

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB278965A (en) 1927-03-24 1927-10-20 Gerhard Haar Improved agricultural plough
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4753788A (en) 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
CH672600A5 (pt) 1985-07-30 1989-12-15 Glaxo Group Ltd
US4946931A (en) 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
EP0504263B1 (en) 1989-12-05 1997-08-13 Ramsey Foundation Neurologic agents for nasal administration to the brain
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
CA2379909C (en) 1999-08-06 2011-01-04 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
AU2001283546A1 (en) 2000-08-14 2002-02-25 Advanced Inhalation Research, Inc. Inhalation device and method
WO2002053190A2 (en) 2000-12-29 2002-07-11 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
RU2292894C2 (ru) 2001-08-14 2007-02-10 Тояма Кемикал Ко., Лтд. Новый способ ингибирования роста вирусов и/или вирулицидный способ и новый аналог пиразиннуклеотида или пиразиннуклеозида
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
WO2003043585A2 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US8001963B2 (en) 2003-09-05 2011-08-23 Kurve Technology, Inc. Integrated nebulizer and particle dispersion chamber for nasal delivery of medicament to deep nasal cavity and paranasal sinuses
KR101216372B1 (ko) 2004-03-30 2013-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌
CN104650077A (zh) 2006-01-17 2015-05-27 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
ES2692396T3 (es) * 2009-06-17 2018-12-03 Vertex Pharmaceuticals Inc. Inhibidores de la replicación de virus de influenza
ES2878087T3 (es) 2012-03-13 2021-11-18 Gilead Sciences Inc Análogos de carba-nucleósido 2-sustituidos para el tratamiento antiviral
CN108276278B (zh) * 2013-11-13 2021-04-20 沃泰克斯药物股份有限公司 制备流感病毒复制抑制剂的方法
JP6718451B2 (ja) 2014-09-08 2020-07-08 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー インフルエンザウィルス感染に使用するためのピロロピリミジン
CN105524067A (zh) 2014-09-28 2016-04-27 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
FR3039227B1 (fr) 2015-07-22 2019-12-27 Safran Aircraft Engines Aeronef comprenant un propulseur arriere carene avec stator d’entree a volets mobiles
EP3362451B1 (en) * 2015-12-09 2023-04-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017198122A1 (zh) * 2016-05-19 2017-11-23 四川大学 抗流感小分子化合物及其制备方法和用途
DE102017000989A1 (de) * 2017-02-03 2018-08-09 Evonik Degussa Gmbh Verfahren zur Herstellung von Cyclododecanon

Also Published As

Publication number Publication date
EP3615545B1 (en) 2021-09-01
AU2018257778B2 (en) 2022-02-17
TW201839003A (zh) 2018-11-01
CN110637022A (zh) 2019-12-31
JP7165721B2 (ja) 2022-11-04
CN110637022B (zh) 2022-09-16
AU2018257778A1 (en) 2019-10-10
CA3059449A1 (en) 2018-11-01
EA039181B1 (ru) 2021-12-15
WO2018200425A1 (en) 2018-11-01
JP2020517738A (ja) 2020-06-18
IL269900B (en) 2022-05-01
PH12019502376A1 (en) 2020-09-14
EA201992543A1 (ru) 2020-03-24
ES2901875T3 (es) 2022-03-24
EP3615545A1 (en) 2020-03-04
KR20190140971A (ko) 2019-12-20
KR102598466B1 (ko) 2023-11-03
US11014941B2 (en) 2021-05-25
DK3615545T3 (da) 2021-11-22
SG11201909478UA (en) 2019-11-28
TWI778052B (zh) 2022-09-21
US20200123177A1 (en) 2020-04-23
NZ757442A (en) 2022-10-28
PL3615545T3 (pl) 2022-01-10
MX2019012759A (es) 2019-12-16

Similar Documents

Publication Publication Date Title
BR112019022307A2 (pt) Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza.
CO2019013042A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019010292A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
CO2019012035A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018006276A2 (pt) composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv.
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
BR112017018977A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de uma infecção por hepatite c ou uma condição resultante de uma infecção por hepatite c, em um hospedeiro em necessidade do mesmo e para fabricação de um medicamento direcionado para uso terapêutico para tratamento de uma infecção pelo vírus da hepatite c, uso de um composto, e, formulação farmacêutica?.
EA201992295A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]